3KY Stoklara Genel Bakış Bir yatırım holding şirketi olan Hansoh Pharmaceutical Group Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Not ekleyinHansoh Pharmaceutical Group Company Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Hansoh Pharmaceutical Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$2.04 52 Haftanın En Yüksek Seviyesi HK$2.86 52 Haftanın En Düşük Seviyesi HK$1.32 Beta 0.65 1 Aylık Değişim -9.73% 3 Aylık Değişim -18.40% 1 Yıllık Değişim n/a 3 Yıllık Değişim 4.62% 5 Yıllık Değişim -31.54% Halka arzdan bu yana değişim 9.03%
Son Haberler & Güncellemeler
Insufficient new directors Dec 30
Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration Nov 27
Investor sentiment deteriorates as stock falls 17% Nov 01
Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 Nov 01
Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC Oct 22
New major risk - Revenue and earnings growth Oct 09 Daha fazla güncelleme görün
Insufficient new directors Dec 30
Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration Nov 27
Investor sentiment deteriorates as stock falls 17% Nov 01
Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093 Nov 01
Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC Oct 22
New major risk - Revenue and earnings growth Oct 09
Investor sentiment improves as stock rises 22% Oct 03
First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023) Sep 27
Upcoming dividend of HK$0.20 per share Sep 13
First half dividend of HK$0.20 announced Aug 29
First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023) Aug 28
Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024 Aug 27
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024 Aug 15
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China Jul 20
Now 27% undervalued Jul 02
Now 21% undervalued Jun 19
Upcoming dividend of HK$0.14 per share Jun 12
Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024 May 01
Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022) Apr 30
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 Apr 30
Now 21% undervalued Apr 29
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer Apr 03
New minor risk - Dividend sustainability Mar 28
Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022) Mar 27
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
Investor sentiment improves as stock rises 15% Feb 17
Insufficient new directors Jan 25
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets Jan 17
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice Nov 11
Investor sentiment improves as stock rises 24% Oct 28
New major risk - Share price stability Oct 25
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections Oct 20
First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022) Oct 01
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105" Sep 26
Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023 Sep 02
Insufficient new directors Sep 01
Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023 Aug 22
New minor risk - Share price stability Aug 08
Investor sentiment deteriorates as stock falls 15% Aug 04
Now 23% undervalued after recent price drop Jul 31
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration Jul 23
Now 23% undervalued after recent price drop Jul 14 Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice Jun 30
Now 23% undervalued after recent price drop Jun 24
Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules Jun 14
Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc Jun 06
Upcoming dividend of HK$0.05 per share at 0.8% yield May 29
Now 21% undervalued after recent price drop May 13
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets" May 06
Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021) Apr 30
Insufficient new directors Apr 21
Now 20% undervalued after recent price drop Apr 05
Full year 2022 earnings released Mar 28
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor Jan 18
Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China Jan 10
Investor sentiment improved over the past week Dec 30
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets" Dec 29
Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib Dec 04
Insufficient new directors Nov 16
Investor sentiment improved over the past week Oct 18
Investor sentiment deteriorated over the past week Sep 03
Upcoming dividend of HK$0.05 per share Sep 01
First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021) Aug 27
Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022 Aug 27
Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Investor sentiment improved over the past week Aug 06
Investor sentiment improved over the past week Jul 22
Investor sentiment improved over the past week Jun 25
Upcoming dividend of HK$0.09 per share Jun 09
Insufficient new directors Jun 02
Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022 May 24
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections May 12
Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020) Mar 30
Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022 Mar 30
Investor sentiment deteriorated over the past week Mar 16
Investor sentiment deteriorated over the past week Jan 27
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets" Dec 29
Hansoh Pharmaceutical Group Company Limited Announces That "Ibrexafungerp Tablets" Has Been Granted A Clinical Trial Dec 16
Investor sentiment deteriorated over the past week Sep 14
Less than half of directors are independent Sep 14
Non-Executive Director Cuifang Ma has left the company Sep 07
First half 2021 earnings released: EPS CN¥0.22 (vs CN¥0.21 in 1H 2020) Aug 28
Investor sentiment deteriorated over the past week Jul 27
Hansoh Pharmaceutical Group Company Limited Receives Approval by the National Medical Products Administration of the People ' S Republic of China for Class 1 Innovative Drug Tenofovir Amibufenamide Tablets Jun 24
Investor sentiment improved over the past week May 21
Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ameile for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer May 14
Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval of "Bortezomib for Injection" May 11
Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019) Apr 29
Hansoh Pharmaceutical Group Company Limited Recommends a Final Dividend for the Year Ended December 31, 2020, Payable on July 5, 2021 Apr 28
Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019) Apr 01
Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 18
SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in China Feb 18
Investor sentiment improved over the past week Jan 09
New 90-day high: €4.18 Jan 08
New 90-day low: €3.44 Dec 10
Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of Saxagliptin Tablets Nov 02
Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Biologics License Application of Inebilizumab Injections by National Medical Products Administration Oct 15 Hissedar Getirileri 3KY DE Pharmaceuticals DE Pazar 7D -4.7% -0.2% -0.4% 1Y n/a -17.1% 7.9%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 3KY un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Getiri vs Piyasa: 3KY un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.
Fiyat Oynaklığı Is 3KY's price volatile compared to industry and market? 3KY volatility 3KY Average Weekly Movement 8.8% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 3KY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 3KY 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Bir yatırım holding şirketi olan Hansoh Pharmaceutical Group Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, anti-tümör, anti-enfeksiyon, merkezi sinir sistemi hastalıkları, onkoloji, metabolik ve otoimmün hastalıklar vb. dahil olmak üzere terapötik alanlar için ürünler sunmaktadır.
Daha fazla göster Hansoh Pharmaceutical Group Company Limited Temel Bilgiler Özeti Hansoh Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 3KY temel i̇stati̇sti̇kler Piyasa değeri €12.33b Kazançlar(TTM ) €624.99m Gelir(TTM ) €1.60b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 3KY gelir tablosu (TTM ) Gelir CN¥12.10b Gelir Maliyeti CN¥1.09b Brüt Kâr CN¥11.01b Diğer Giderler CN¥6.30b Kazançlar CN¥4.71b
Temettüler
2.3% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/03 16:17 Gün Sonu Hisse Fiyatı 2025/01/03 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Hansoh Pharmaceutical Group Company Limited 33 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Sharon Shi BOCI Research Ltd. Bo Li BofA Global Research Jin Zhang China International Capital Corporation Limited
Göster 30 daha fazla analist